R. Tirouvanziam

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “384 Impact of elexacaftor/tezacaftor/ivacaftor therapy on pathological reprogramming of lung-recruited neutrophils conditioned by cystic fibrosis airway fluid”.

384 Impact of elexacaftor/tezacaftor/ivacaftor therapy on pathological reprogramming of lung-recruited neutrophils conditioned by cystic fibrosis airway fluid

Journal of Cystic Fibrosis(2022)10.1016/s1569-1993(22)01074-8

N/A

0DataRank · unranked

0 citations

D. Moncada Giraldo, G. Collins, S. Kim, J. Chandler, R. Tirouvanziam +1 more

221 Elexacaftor-tezacaftor-ivacaftor did not curtail sputummyeloperoxidase in a cohort of adults with cystic fibrosis

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01151-7

N/A

0DataRank · unranked

0 citations

Diego Moncada Giraldo, Alexandre Cammarata-Mouchtouris, R. Tirouvanziam, J. Chandler, G. Collins

172 Epidermal growth factor receptor–inducible nitric oxide synthase signaling axis modulates bacterial killing in cystic fibrosis airway neutrophils

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01103-7

N/A

0DataRank · unranked

0 citations

Jonathan L. Koff, R. Tirouvanziam, Amit Gaggar, Camilla Margaroli, Yixel Soto-Vázquez